From: Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Study author, year [reference] | Galli, 2017 [66] | Brunnemer, 2018 [110] | Bonella, 2016 [85] | Barczi, 2019 [67] | Tzouvelekis, 2018 [86] | Kreuter, 2017 [113] |
---|---|---|---|---|---|---|
Number of patients | 57 | 64 | 62 | 22 | 94 | 623 |
Comorbidities, n (%) | ||||||
 Arterial hypertension |  | 28 (43.8) | 19 (31) | 14 (63.6) | 41 (43.6) |  |
 PH | 11 (19.3) | 5 (7.8) |  | 9 (40.9) | 16 (17.0) |  |
 Congestive heart failure | 4 (7) |  |  |  |  |  |
 IHD | 14 (24.6) | 21 (32.8) | 8 (13) | ≤5 (22.7)a | 20 (21.3) |  |
 Diabetes mellitus | 15 (26.3) | 16 (25) | 9 (14.5) | 4 (18.2) | 18 (19.1) |  |
 GERD | 31 (54.4) | 21 (32.8) | 7 (11) | 2 (9.1) | 38 (40.4) | 192 (30.8) |
 OSA |  | 9 (14.1) | 4 (6) |  |  |  |
 Emphysema | 12 (21.1) | 9 (14.1) |  |  |  | 55 (8.8) |
 Stroke |  | 2 (3.1) |  |  |  |  |
Concomitant medications, n (%) | ||||||
 Prednisone | 10 (17.5) |  |  |  |  |  |
 Anti-acid therapy | 37 (64.9) | 22 (34.4) (PPI) | 16 (26) (PPI) |  |  |  |
 Anticoagulant | 7 (12.3) | 7 (10.9) | 2 (3) |  |  |  |
 Aspirin + anticoagulant |  | 3 (4.7) |  |  |  |  |
 N-acetyl cysteine |  |  | 5 (8) |  |  |  |
 MMF | 5 (8.8) |  |  |  |  |  |
 Sildenafil/tadalafil | 6 (10.5) |  |  |  |  |  |
 Anti-hypertensive |  | 28 (43.8) | 19 (31) |  |  |  |